Fig. 3

CCK-8 assay for detecting the proliferative activity of ECs and SMCs. a Ecs: the proliferative activity of ECs was significantly enhanced after treatment with FGF18 (p < 0.05); the proliferative activity of ECs was higher in the NC + LV-Itgβ1 + FGF18 group than in the NC + LV-Itgβ1, NC + FGF18, and NC groups (p < 0.05); amongst the groups that were not treated with FGF18, the proliferative activity of ECs in the NC + LV-Itgβ1 group was the strongest, whereas that in the NC + LV-Itgβ1-RNAi group was the weakest. b SMCs: FGF18 alone could not improve the proliferative activity of SMCs in the NC and NC + LV-Con groups (p = 0.127, 0.082); FGF18 improved the proliferative activity of SMCs in the NC + LV-Itgβ1 group (p = 0.032); the proliferative activity of SMCs was higher in the NC + LV-Itgβ1 group than in the NC and NC + LV-Con groups (p = 0.012, 0.024); the proliferative activity of SMCs was higher in the NC + LV-Itgβ1 + FGF18 group than in the NC, NC + LV-Itgβ1, and NC + FGF18 groups (p < 0.05)